Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare hematology diseases, centered on mavorixafor, an oral CXCR4 antagonist marketed in the U.S. as XOLREMDI® in its first indication. Company news covers regulatory and commercial updates for XOLREMDI, including European authorization for WHIM syndrome and the Norgine license and supply relationship for selected ex-U.S. territories.
Recurring updates also address the 4WARD Phase 3 program evaluating mavorixafor in chronic neutropenia, quarterly financial results, product revenue, research and development spending, cash resources, restructuring effects, conference participation, and equity inducement grants under Nasdaq listing rules.
X4 Pharmaceuticals (Nasdaq: XFOR), focused on rare immune system diseases, announced its participation in the Stifel 2024 Healthcare Conference in New York. The company will engage in a fireside chat on Monday, November 18, 2024, at 4:10 PM ET at the Lotte New York Palace. A live webcast will be available through X4's website's investor section, with a replay accessible after the event. The company will also be available for one-on-one meetings with investors, which can be arranged through Stifel representatives.
X4 Pharmaceuticals (XFOR) reported Q3 2024 financial results and corporate updates. The company announced positive Phase 2 results for mavorixafor in chronic neutropenia (CN) and continues enrollment in its Phase 3 4WARD trial, expected to complete by mid-2025. Following XOLREMDI's U.S. approval in April 2024, X4 generated initial product revenue of $0.6 million. The company reported a net loss of $36.7 million and holds $135.8 million in cash, sufficient to support operations into late 2025. X4 plans to submit a Marketing Authorization Application to the EMA for WHIM syndrome by early 2025.
X4 Pharmaceuticals (XFOR) announced positive results from its completed six-month Phase 2 trial of mavorixafor in Chronic Neutropenia (CN). The study demonstrated that mavorixafor durably increased participants' mean absolute neutrophil counts (ANC) to normal levels. In combination therapy, it enabled substantial G-CSF dosing reductions (52% at Month 3 and 70% at Month 6) while maintaining normal ANC levels. A sub-study showed that neutrophils mobilized by mavorixafor were as functional as those from healthy donors. The drug was generally well tolerated with no drug-related serious adverse events reported.
X4 Pharmaceuticals (XFOR) has granted inducement awards to new employees under its 2019 Inducement Plan. The awards consist of options to purchase 271,764 shares of common stock at an exercise price of $0.5002 per share, equal to the closing price on October 31, 2024. The options have a ten-year term and will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (Nasdaq: XFOR) has announced it will report its third-quarter 2024 financial results and present findings from its completed Phase 2 clinical trial of mavorixafor in chronic neutropenia patients on November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. ET on the same day. The presentation will be accessible via phone and through the company's investor relations website, with a replay available afterward.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 744,468 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.6693 per share, equal to the closing price on September 30, 2024.
The options will vest over a four-year period, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, granted on August 30, 2024, consist of options to purchase 230,588 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.70 per share, equal to the closing price of X4's stock on the grant date. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and was approved by X4's Compensation Committee.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on rare immune system diseases, has announced its participation in three major investor conferences in September 2024. These include:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- Wells Fargo Healthcare Conference on September 5
- Cantor Fitzgerald Global Healthcare Conference on September 17
The company will engage in fireside chats and one-on-one meetings at these events. Live webcasts for the Morgan Stanley and Cantor Fitzgerald conferences will be available on X4's website, with replays accessible afterwards. Investors interested in one-on-one meetings should contact their respective conference representatives.
X4 Pharmaceuticals (Nasdaq: XFOR) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. First U.S. commercial sales of XOLREMDI™ (mavorixafor) following FDA approval in April 2024 for WHIM syndrome.
2. Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full results expected in November 2024.
3. Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia.
4. Recognized a $105 million gain from the sale of a priority review voucher.
5. Reported net income of $90.8 million for Q2 2024, compared to a net loss of $55.7 million in Q2 2023.
6. Cash position of $169.5 million as of June 30, 2024, expected to support operations into late 2025.
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 708,236 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.8001 per share, equal to the closing price on July 31, 2024. The options will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employees.